Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Accounts Payables (2016 - 2025)

Ligand Pharmaceuticals' Accounts Payables history spans 16 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 38.12% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $3.2 million, down 38.12%, while the annual FY2025 figure was $3.2 million, 38.12% down from the prior year.
  • Accounts Payables for Q4 2025 was $3.2 million at Ligand Pharmaceuticals, down from $3.7 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $19.2 million in Q2 2022 and bottomed at $1.8 million in Q2 2024.
  • The 5-year median for Accounts Payables is $5.4 million (2025), against an average of $7.2 million.
  • The largest annual shift saw Accounts Payables plummeted 84.42% in 2023 before it skyrocketed 183.47% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $8.4 million in 2021, then tumbled by 36.84% to $5.3 million in 2022, then plummeted by 54.27% to $2.4 million in 2023, then soared by 115.62% to $5.2 million in 2024, then crashed by 38.12% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Accounts Payables are $3.2 million (Q4 2025), $3.7 million (Q3 2025), and $5.4 million (Q1 2025).